100 years after the discovery of insulin, JDRF is pleased to announce the results of the first annual Beyond Insulin Vote for Research.
Beyond Insulin™ invests $25,600 in CREATE
Bringing Progress to Life: Type 1 Diabetes Research Symposium
JDRF’s mission of improving lives and curing type 1 diabetes (T1D) cannot be achieved alone. It requires us to engage with stakeholders who believe in what we have set out to do and are able to help drive our mission forward – and this group includes regulators. JDRF recognizes the importance of engaging with regulators in order to to help shape and provide clear and reasonable pathways to scientific research and therapy approvals for T1D treatment and cure therapies.
Bringing Breakthroughs to Life: Type 1 Diabetes Research Symposium
JDRF’s mission of improving lives and curing type 1 diabetes (T1D) cannot be achieved alone. It requires us to engage with stakeholders who believe in what we have set out […]
Thriving with Diabetes
Halloween day will never be the same for Conrad Pow as that was the day in 2018 when his daughter Chloe was diagnosed with type 1 diabetes (T1D).
British Columbians speak out about #AccessForAll in online community consultations
This past month, as part of JDRF’s #AccessforAll campaign, British Columbians impacted by type 1 diabetes (T1D) came together with patient advocates, clinicians and elected officials to discuss the benefits of continuous glucose monitoring (CGM) and flash glucose monitoring (Flash GM) devices, and the need to cover these technologies under B.C. Pharmacare.
An update on JDRF’s Advocacy Efforts: #AccessForAll
Our #AccessForAll campaign has been keeping busy, finding new and creative ways to advocate government officials at the provincial level despite the constraints of COVID-19. To everyone who has supported by volunteering time, talents or donations– thank you.
Celebrating our women researchers on International Women’s Day
March 8 marks International Women’s Day (IWD) globally. This 2021 campaign theme is #ChooseToChallenge.
Biosimilar Insulins – What you need to know
For anyone impacted by type 1 diabetes (T1D), the term ‘biosimilars’ is one that will become increasingly familiar now that the patents of some biologic insulins are expiring. This means that biosimilar versions of these insulins may be approved, and some are already on the North American market.
Monitoring Your Child’s Glucose Remotely
Like most parents after their child has been diagnosed with Type 1 diabetes, Cindy Voss found herself overwhelmed, anxious and exhausted. With an active 10-year old whose glucose levels would drop quickly and unexpectedly, Cindy found herself constantly worrying and would get up every couple of hours throughout the night to prick her son Mathew’s finger to get a blood sugar reading.
Ustekinumab, A Potentially Disease Modifying Drug for Type 1 Diabetes, Is Being Tested in Clinical Trials in Canada
A JDRF-funded clinical trial is examining whether a drug currently (ustekinumab; pronounced oos·teh·KIN·yoo·mab) used for the treatment of psoriasis (which affects the skin), Crohn’s disease (an inflammatory bowel disease), and other autoimmune conditions can also work for type 1 diabetes.
JDRF Advocacy Efforts to Ensure COVID-19 Vaccination Priority for the Type 1 Diabetes Community
We’ve received many questions about the COVID-19 vaccination rollout in provinces and territories across Canada, and specifically at what stage people living with type 1 diabetes (T1D) should expect to receive theirs.
Exciting new updates in JDRF funded research of Sernova’s Cell Pouch System
On January 15, 2021 Sernova announced that patients in their ongoing clinical trial show persistent islet function and clinically meaningful improvement in glucose control.
